Conference Coverage

Immunogenicity of two-dose Gardasil 9 persists at 36 months

Publish date: July 13, 2018

 

REPORTING FROM ESPID 2018

Pages

Recommended Reading

NIAID proposes 3-pronged plan for universal influenza vaccine
MDedge ObGyn
2 new influenza strains recommended for next season
MDedge ObGyn
Maternal biologic therapy does not affect infant vaccine responses
MDedge ObGyn
Phase 2 ‘universal flu vaccine’ trial announced
MDedge ObGyn
Cochrane report: HPV vaccine proves its worth in adolescent, young adult women
MDedge ObGyn
MDedge Daily News: Do HPV vaccines really cut cancer risk?
MDedge ObGyn
Persistent providers sway parents to accept HPV vaccination
MDedge ObGyn
NIH launches early Ebola treatment trial
MDedge ObGyn
ACIP votes to recommend new strains for the 2018-2019 flu vaccine
MDedge ObGyn
Parents say cancer prevention is the best reason to give HPV vaccine
MDedge ObGyn